Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
- Conditions
- Alcohol Use Disorder
- Interventions
- Drug: Placebo to match sunobinop
- Registration Number
- NCT06545916
- Lead Sponsor
- Imbrium Therapeutics
- Brief Summary
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo to match sunobinop Placebo to match sunobinop - Sunobinop Sunobinop -
- Primary Outcome Measures
Name Time Method Percent heavy drinking days (HDD) Day 57
- Secondary Outcome Measures
Name Time Method Number of standard unit drinks Day 57 Percent of drinking days (PDD) Day 57
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (6)
Inquest Clinical Research
🇺🇸Baytown, Texas, United States
Bio Terra Med SRL
🇷🇴Bucharest, Romania
Spitalul Universitar De Urgenta Militar Central "Dr. Carol Davila"
🇷🇴Bucharest, Romania
Cabinet Medical Individual Dr. Andreea Popa
🇷🇴Bucharest, Romania
Belmont Medical Office
🇺🇸Brooklyn, New York, United States
Cebis Usa, Llc
🇺🇸Houston, Texas, United States
Inquest Clinical Research🇺🇸Baytown, Texas, United StatesCentral ContactContact